Market Exclusive

Analyst Activity – Aegis Reiterates Buy on Inovio Pharmaceuticals (NASDAQ:INO)

Analyst Ratings For Inovio Pharmaceuticals (NASDAQ:INO)

Today, Aegis reiterated its Buy rating on Inovio Pharmaceuticals (NASDAQ:INO) with a price target of $14.00.

There are 2 hold ratings, 7 buy ratings on the stock.

The current consensus rating on Inovio Pharmaceuticals (NASDAQ:INO) is Buy (Score: 2.78) with a consensus target price of $22.11 per share, a potential 184.57% upside.

Some recent analyst ratings include

Recent Insider Trading Activity For Inovio Pharmaceuticals (NASDAQ:INO)
Inovio Pharmaceuticals (NASDAQ:INO) has insider ownership of 10.60% and institutional ownership of 27.74%.

Recent Trading Activity for Inovio Pharmaceuticals (NASDAQ:INO)
Shares of Inovio Pharmaceuticals closed the previous trading session at 7.84 up +0.07 0.95% with 593,640 shares trading hands.

Exit mobile version